These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 33720084)

  • 1. Immunohistochemistry and Next-generation Sequencing Are Complementary Tests in Identifying PTEN Abnormality in Endometrial Carcinoma Biopsies.
    Wang L; Piskorz A; Bosse T; Jimenez-Linan M; Rous B; Gilks CB; Brenton JD; Singh N; Köbel M
    Int J Gynecol Pathol; 2022 Jan; 41(1):12-19. PubMed ID: 33720084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing.
    Djordjevic B; Hennessy BT; Li J; Barkoh BA; Luthra R; Mills GB; Broaddus RR
    Mod Pathol; 2012 May; 25(5):699-708. PubMed ID: 22301702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between PTEN, DNA mismatch repair, and tumor histotype in endometrial carcinoma: retained positive expression of PTEN preferentially identifies sporadic non-endometrioid carcinomas.
    Djordjevic B; Barkoh BA; Luthra R; Broaddus RR
    Mod Pathol; 2013 Oct; 26(10):1401-12. PubMed ID: 23599155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies.
    Singh N; Piskorz AM; Bosse T; Jimenez-Linan M; Rous B; Brenton JD; Gilks CB; Köbel M
    J Pathol; 2020 Mar; 250(3):336-345. PubMed ID: 31829441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histotype-genotype correlation in 36 high-grade endometrial carcinomas.
    Hoang LN; McConechy MK; Köbel M; Han G; Rouzbahman M; Davidson B; Irving J; Ali RH; Leung S; McAlpine JN; Oliva E; Nucci MR; Soslow RA; Huntsman DG; Gilks CB; Lee CH
    Am J Surg Pathol; 2013 Sep; 37(9):1421-32. PubMed ID: 24076778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Many Uses of p53 Immunohistochemistry in Gynecological Pathology: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual9 Meeting.
    Köbel M; Kang EY
    Int J Gynecol Pathol; 2021 Jan; 40(1):32-40. PubMed ID: 33290354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Immunohistochemistry to Distinguish Grade 3 Endometrioid Carcinoma and Uterine Serous Carcinoma.
    Zaidi A; Gupta P; Gupta N; Rajwanshi A; Rai B; Gainder S
    Appl Immunohistochem Mol Morphol; 2020 Jan; 28(1):42-48. PubMed ID: 31815745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of endometrial carcinoma on biopsy as a predictor of final surgical pathology: Are we doing it right? A completed audit cycle and recommendations.
    Jassar A; Hemali N; Bhatnagar A
    Indian J Pathol Microbiol; 2024; 67(1):68-73. PubMed ID: 38358191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients.
    Westin SN; Ju Z; Broaddus RR; Krakstad C; Li J; Pal N; Lu KH; Coleman RL; Hennessy BT; Klempner SJ; Werner HM; Salvesen HB; Cantley LC; Mills GB; Myers AP
    Mol Oncol; 2015 Oct; 9(8):1694-703. PubMed ID: 26045339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of PTEN in endometrial liquid-based cytology.
    Di Lorito A; Zappacosta R; Capanna S; Gatta DM; Rosini S; Schmitt FC
    Acta Cytol; 2014; 58(5):495-500. PubMed ID: 25358681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathologic scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducible.
    Garg K; Broaddus RR; Soslow RA; Urbauer DL; Levine DA; Djordjevic B
    Int J Gynecol Pathol; 2012 Jan; 31(1):48-56. PubMed ID: 22123723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunohistochemical expression of PTEN antigen: a new tool for diagnosis of early endometrial neoplasia].
    Taranger-Charpin C; Carpentier S; Dales JP; Garcia S; Djemli A; Andrac L; Lavaut MN; Sferlazzo K; Boubli L
    Bull Acad Natl Med; 2004; 188(3):415-27; discussion 427-9. PubMed ID: 15584653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PTEN and p53 abnormalities are indicative and predictive factors for endometrial carcinoma.
    Inaba F; Kawamata H; Teramoto T; Fukasawa I; Inaba N; Fujimori T
    Oncol Rep; 2005 Jan; 13(1):17-24. PubMed ID: 15583796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alteration of PTEN expression in endometrial carcinoma is associated with down-regulation of cyclin-dependent kinase inhibitor, p27.
    An HJ; Lee YH; Cho NH; Shim JY; Kim JY; Lee C; Kim SJ
    Histopathology; 2002 Nov; 41(5):437-45. PubMed ID: 12405911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles.
    McConechy MK; Ding J; Senz J; Yang W; Melnyk N; Tone AA; Prentice LM; Wiegand KC; McAlpine JN; Shah SP; Lee CH; Goodfellow PJ; Gilks CB; Huntsman DG
    Mod Pathol; 2014 Jan; 27(1):128-34. PubMed ID: 23765252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological and molecular characteristics of endometrial neuroendocrine carcinomas reveal preexisting endometrial carcinoma origin.
    Ono K; Kasajima R; Katayama K; Miyagi Y; Yokose T
    Pathol Int; 2021 Aug; 71(8):491-499. PubMed ID: 34015161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: a potential target treatment.
    Peiró G; Peiró FM; Ortiz-Martínez F; Planelles M; Sánchez-Tejada L; Alenda C; Ceballos S; Sánchez-Payá J; Laforga JB
    Hum Pathol; 2013 Feb; 44(2):218-25. PubMed ID: 22955108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma.
    Stelloo E; Nout RA; Naves LC; Ter Haar NT; Creutzberg CL; Smit VT; Bosse T
    Gynecol Oncol; 2014 May; 133(2):197-204. PubMed ID: 24556061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression.
    Huang HN; Lin MC; Tseng LH; Chiang YC; Lin LI; Lin YF; Huang HY; Kuo KT
    Histopathology; 2015 Mar; 66(4):517-28. PubMed ID: 25195947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations.
    Murali R; Davidson B; Fadare O; Carlson JA; Crum CP; Gilks CB; Irving JA; Malpica A; Matias-Guiu X; McCluggage WG; Mittal K; Oliva E; Parkash V; Rutgers JKL; Staats PN; Stewart CJR; Tornos C; Soslow RA
    Int J Gynecol Pathol; 2019 Jan; 38 Suppl 1(Iss 1 Suppl 1):S40-S63. PubMed ID: 30550483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.